1 Min Read
Jan 9 (Reuters) - Exelixis Inc :
* Update on dispute between Exelixis and Genentech, a member of the Roche group
* Exelixis relieved of $18.7 million of disputed costs
* Genentech withdrew counterclaim against company in ongoing JAMS arbitration concerning "alleged breaches of parties' collaboration agreement"
* Genentech's action does not address claims related to its clinical development, pricing and promotional costs for COTELLIC in United States
* Genentech has not confirmed how it will allocate promotional costs with respect to collaboration's promotion of other combination therapies Source text for Eikon: Further company coverage: